Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Ethicon, Inc. is a subsidiary of Johnson & Johnson. It was incorporated as a separate company under the Johnson & Johnson umbrella in 1949 to expand and diversify the Johnson & Johnson product line. Ethicon has manufactured surgical sutures and wound closure devices since 1887. After World War II, Ethicon's market share in surgical sutures rose from 15% to 70% worldwide. In the United States, the market share is approximately 80%.

The Research Authority serves as the administrative and financial framework for research activities, scientific experiments and technical analyses carried out by Technion faculty, and TRDF staff. The missions of the Research & Development Division are: - Location, collection, processing and distribution of information concerning local and international research funding - Assistance in locating appropriate funding sources for Technion researchers - R&D information management services and in-campus marketing - Guidance and administrative services for Technion researchers in submitting research proposals to granting agencies and business entities - Management of contractual engagements with granting agencies and business entities - Contractual and budgetary administration of research grants and other accounts

Sunnybrook Health Sciences Centre owns and manages hospitals. It operates as an academic health sciences center. The firm?s services encompass treating and preventing cancer, cardiovascular disease, neurological disorders, orthopedic and arthritic conditions, and traumatic injuries. It focuses on areas of heart and stroke, cancer, trauma, emergency, and critical care, and women and babies. The firm caters to the war veterans, high risk pregnancies, critically-ill newborns, adults, and the elderly. The company was founded on June 12, 1948 and is headquartered in Toronto, Canada.

ACell, Inc. develops and manufactures bioscaffold, extracellular matrix technology for medical and veterinary products. It offers the next generation of regenerative medicine through the development and commercialization of unique extracellular matrix devices to repair and remodel damaged tissues and organs in a broad range of surgical procedures. The firm's products include ABRA, Cytal Burn Matrix, Cytal Wound Matrix, Gentrix Surgical Matrix and MicroMatrix. It is a regenerative medicine company that focuses on the development, manufacturing and sale of products primarily used in acute care settings as part of the treatment and management of moderate to severe wounds and reinforcement of soft tissue surgical defects. The firm’s products utilizes proprietary porcine urinary bladder matrix platform technology, which is designed to enhance the body's ability to restore natural tissue and minimize scarring in the management of traumatic, surgical and chronic wounds, burns, hernias and other conditions requiring the reinforcement of soft tissue. The company was founded by Stephen Xavier Graham in June 1999 and is headquartered in Columbia, MD.

3M Innovative Properties Co. acquires and manages intellectual property right. It engages in the acquisition and ownership of the intellectual property rights to the products designed and manufactured by its parent company 3M Corporation. The company was founded on May 10, 1999 and is headquartered in Roseville, MN.

BIOPHARM Gesellschaft zur biotechnologischen Entwicklung is a German private company located in Eppelheim. The firm operates as a biotechnology development company. It was founded in 1986 by Michael Paulista, he has been the CEO since the inception date.\nThe company says this about itself: BIOPHARM is one of the pioneers in the research and development of biotechnological drug substances. Our platform technology of recombinant human growth factors combines our expertise and experience of more than 30 years with innovative applications in the field of orthopedics, dermatology and personalized medicine.

Organogenesis Inc. is a regenerative medicine company with the unique skill set to take complex, living therapies from research and development (R&D), through manufacturing, to successful commercialization to reach patients today. As a pioneer in the field of regenerative medicine, Organogenesis received the first FDA approval of a living, allogeneic, cell based product (Apligraf®, approved for the treatment of venous leg ulcers). Apligraf is now the leading regenerative medicine product in the world, with two FDA-approved indications. In 2012 we received an FDA approval for GINTUIT™, a living, human cell-based product that represents a new therapeutic class in dentistry.

CorMatrix Cardiovascular is a privately held medical device company that is dedicated to developing and delivering innovative biomaterial devices that harness the body’s own innate ability to repair damaged heart tissue. The company is currently researching, developing, and commercializing a platform technology, known as CorMatrix ECM, for a variety of cardiovascular indications. Incorporated in December of 2001, CorMatrix was co-founded by David Camp, an entrepreneurial executive in the cardiovascular medical device field, and Robert G. Matheny, MD, a cardiothoracic surgeon and co-inventor on several patents related to extracellular matrix (ECM) technology. Dr. Matheny’s interest and experience with these unique materials began at Purdue University in the 1990s while he was a private practice cardiac surgeon in Indianapolis. Realizing the potential of extracellular matrix materials for cardiovascular surgery, he further increased his study and preclinical work in matrix materials and tissue repair.

Engages in priniting activities

Xenogen Corporation is a biotechnology company offering an integrated suite of biophotonic real-time in vivo imaging and genetic modification technologies that can help expedite drug discovery and development, and significantly reduce the cost and time to market for new therapies. Xenogen's VivoVision(TM) Systems non-invasively illuminate and monitor biological processes within living mammals, at the molecular level, in real time. The technology is designed to provide higher quality in vivo data earlier in the drug discovery and development process. VivoVision(TM) Solutions are designed to improve discovery and pre-clinical research in multiple therapeutic areas. VivoVision(TM) Biosciences represents more than 15 years of experience in the creation and characterization of animal models, including genetic modifications, comprehensive phenotyping, compound profiling and custom design and production of light producing cells, microorganisms and animals.

Avery Dennison Corporation (Avery Dennison), is engaged in the production of pressure-sensitive materials, and a variety of tickets, tags, labels other converted products, and office and consumer products through embossing, printing, stamping and die-cutting. The Company operates in two segments: Pressure-sensitive Materials and Retail Branding and Information Solutions. In addition to its reportable segments, the Company has other specialty converting businesses comprised of Vancive Medical Technologies (Vancive) and Designed and Engineered Solutions (DES). Some are sold by the Company in converted form as printable media, tapes and reflective sheeting. In July 2013, Avery Dennison Corp completed the sale of its Office and Consumer Products and Designed and Engineered Solutions businesses to CCL Industries Inc.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

The American Can Company was a manufacturer of tin cans. It was a member of the Tin Can Trust, that controlled a "large percentage of business in the United States in tin cans, containers, and packages of tin." American Can Company ranked 97th among United States corporations in the value of World War II military production contracts. It was formerly a member of the Dow Jones Industrial Average from 1959–1991, though after 1987 it had renamed itself Primerica, a financial conglomerate which had divested itself of its packaging arm in 1986.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Synovis Life Technologies, Inc. manufactures medical devices. It markets biological and mechanical products used by surgical specialties to facilitate the repair and reconstruction of soft tissue damaged or destroyed by disease or injury. The company was founded in July 1985 and is headquartered in St. Paul, MN.

Sigma Aldrich Co. Ltd. engages in the science and technology company. Its products include analytical standards, gas chromatography, spectroscopy, acids and bases, catalysis and inorganics, organometallics, solvents, antibodies, biochemical and reagents, cell biology, microbiology, and polymer sciences. It also offers basic research, product and process development, manufacturing and production, and regulatory compliance services. The company was founded on December 10, 1987 and is headquartered in Gillingham, the United Kingdom.

Operates as a biotechnology company that manufactures therapeutics for cancer and immunological diseases

DiscGenics, Inc. operates as a regenerative medicine company. It focuses on the devlopment of therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. The company was founded in 2007 and is headquartered in Salt Lake City, UT.